Rezolute is trading at $3.66, down 6.69%, as a broad market selloff appears to be the likelier context; no confirmed company-specific catalyst surfaced.
- Nasdaq’s listed company updates include an October 15 clinical-trial update, not a November 5 announcement.
- The S&P 500, Nasdaq, and Dow were lower, while biotech was up.
- Intraday volume and trading-activity details were not provided.